Form 4: Tivic Health Director Granted Stock Options

Tivic Health Systems Director Dean Zikria was granted 7,500 stock options with an exercise price of $3.32, vesting over one year.

Summary

• Director Dean Zikria of Tivic Health Systems, Inc. (TIVC) was granted 7,500 stock options.
• The options have an exercise price of $3.32 per share.
• The grant date for these options is August 6, 2025.
• The options will expire on August 5, 2035.
• Vesting occurs in four equal quarterly installments, with full vesting achieved on the first anniversary of the grant date.

Sentiment

Score: 6

Explanation: The filing reports a routine grant of stock options to a director, which is a standard compensation practice aimed at aligning management incentives with shareholder interests. It does not contain significant operational or financial news.

Positives

• Granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Negatives

• The value of the options is contingent on the future appreciation of the common stock above the $3.32 exercise price.
• The options are not immediately exercisable and require future stock price appreciation to be in-the-money.

Risks

• The value of the stock options is contingent on the future appreciation of Tivic Health Systems, Inc.'s common stock above the $3.32 exercise price.
• If the stock price does not exceed the exercise price, the options may expire worthless.
• The vesting schedule means the director must remain with the company for at least one year to fully realize the options.

Future Outlook

The granting of stock options with a future vesting schedule indicates a long-term incentive for the director, aligning their future performance with shareholder value creation.

Industry Context

Stock option grants are a standard form of executive and director compensation in the technology and healthcare sectors, used to attract, retain, and incentivize key personnel by linking their compensation to company performance.

Comparison to Industry Standards

• The grant of 7,500 options to a director is a common practice for companies of Tivic Health Systems' size, comparable to similar grants seen at small to mid-cap medical device or health technology companies.
• An exercise price of $3.32, if at or above the market price on the grant date, is standard for incentive stock options.
• A 10-year expiration period is typical for employee and director stock options in the U.S. market.
• Quarterly vesting over one year is a common accelerated vesting schedule for director grants, often seen in companies like InMode Ltd. (INMD) or Inspire Medical Systems, Inc. (INSP) for their non-employee directors.

Related Party Transactions

• Grant of 7,500 stock options to Dean Zikria, a director of Tivic Health Systems, Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases. It could lead to minor dilution upon exercise.

Next Steps

• The stock options will vest in four equal quarterly installments over the next year, starting from August 6, 2025.
• The director will be able to exercise vested options to purchase common stock at $3.32 per share.

Key Dates

Recommendation

This Form 4 filing details a standard stock option grant to a director, which is a routine compensation event and does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The grant aligns the director's incentives with long-term shareholder value, but it's not a catalyst for immediate price movement.

Keywords

Tivic Health Systems, TIVC, Stock Options, Director Compensation, SEC Form 4, Insider Trading, Equity Grant, Beneficial Ownership